NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

Cover of Drugs and Lactation Database (LactMed)

Drugs and Lactation Database (LactMed) [Internet].

Show details

Ofatumumab

Last Revision: December 3, 2018.

Estimated reading time: 1 minute

CASRN: 679818-59-8

Drug Levels and Effects

Summary of Use during Lactation

No information is available on the clinical use of ofatumumab during breastfeeding. Because ofatumumab is a large protein molecule with a molecular weight of 149,000, the amount in milk is likely to be very low and absorption is unlikely because it is probably destroyed in the infant's gastrointestinal tract. Until more data become available, ofatumumab should be used with caution during breastfeeding, especially while nursing a newborn or preterm infant.

Ofatumumab is a human immunoglobulin G1 (IgG1) kappa antibody. Holder pasteurization (62.5 degrees C for 30 minutes) decreases the concentration of endogenous immunoglobulin G by up to 79%.[1][2] A study of 67 colostrum samples that underwent Holder pasteurization found that IgG amounts decreased by 34 to 40%. Specific IgG subclasses decreased by different amounts, with IgG1 activity decreasing by about 37%.[3] None of the studies measured IgG activity.

Drug Levels

Maternal Levels. Relevant published information was not found as of the revision date.

Infant Levels. Relevant published information was not found as of the revision date.

Effects in Breastfed Infants

Relevant published information was not found as of the revision date.

Effects on Lactation and Breastmilk

Relevant published information was not found as of the revision date.

References

1.
Koenig A, de Albuquerque Diniz EM, Barbosa SF et al. Immunologic factors in human milk: The effects of gestational age and pasteurization. J Hum Lact. 2005;21:439-43. [PubMed: 16280560]
2.
Adhisivam B, Vishnu Bhat B, Rao K et al. Effect of Holder pasteurization on macronutrients and immunoglobulin profile of pooled donor human milk. J Matern Fetal Neonatal Med. 2018;1-4. [PubMed: 29587541]
3.
Rodriguez-Camejo C, Puyol A, Fazio L et al. Antibody profile of colostrum and the effect of processing in human milk banks: Implications in immunoregulatory properties. J Hum Lact. 2018;34:137-47. [PubMed: 28586632]

Substance Identification

Substance Name

Ofatumumab

CAS Registry Number

679818-59-8

Drug Class

  • Breast Feeding
  • Antibodies, Monoclonal

Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.

Views

Related information

Similar articles in PubMed

  • Review Daratumumab[Drugs and Lactation Database (...]
    Review Daratumumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Golimumab[Drugs and Lactation Database (...]
    Review Golimumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Guselkumab[Drugs and Lactation Database (...]
    Review Guselkumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Durvalumab[Drugs and Lactation Database (...]
    Review Durvalumab
    . Drugs and Lactation Database (LactMed). 2006
  • Review Benralizumab[Drugs and Lactation Database (...]
    Review Benralizumab
    . Drugs and Lactation Database (LactMed). 2006
See reviews...See all...

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...